Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.56+0.02 (+3.54%)
Close on Nov 17, 2026Market cap $77.98MP/E –Yield –
Earnings
Rani Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$1.70M
EPS, Q3 FY2026
-$0.04
-$0.12 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Rani Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $1.70M | – | -$0.04 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026during market hours | $1.70M | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026during market hours | $1.70M | +750.0% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026during market hours | $1.50M | +50.0% | -$0.07 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | – | – | -$0.12 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | -$0.18 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025during market hours | $200.00K | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025during market hours | $1.00M | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | – | – | -$0.24 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024during market hours | – | – | -$0.29 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 20, 2024during market hours | – | – | -$0.27 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | – | – | -$0.36 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 11, 2023during market hours | – | – | -$0.37 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023during market hours | – | – | -$0.35 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022during market hours | – | – | -$0.33 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | – | – | -$0.31 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022during market hours | – | – | -$0.29 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022during market hours | – | – | -$0.27 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 16, 2021after the close | – | – | -$0.16 | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 13, 2021during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Rani Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Rani Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Rani Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Update
- Update
- Results
See a number that looks wrong?